MRI ANALYZER
END TO END PIPELINE FOR CANCER DIAGNOSIS
Helping Medical Professionals Identify and Diagnose Cancer
VISION
The MRI Analyzer team’s mission is to aid medical professionals when identifying prostate cancer and determining the best course of follow up actions. MRI Analyzer offers flexibility to patients who only have a partial data record available, qualifies its predictions with uncertainty estimates at each step, and matches in-practice metrics of cancer diagnosis. This has the ability to both increase the speed with which readings can be performed while maintaining performance and usefulness in a variety of healthcare scenarios.
TEAM
AIdan jackson
aidanjackson@berkeley.edu
Dhyani Parekh
dhyanip7@berkeley.edu
PIOTR PARKITNY
pparkitny@berkeley.edu
CANDICE SENER
senercansu@berkeley.edu
Conditions of Use
THIS SITE DOES NOT CONTAIN MEDICAL ADVICE
The contents of This Site, such as text, graphics, images, and other materials created and contained on This Site (collectively, “Content”) are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on This Site!
DATA INTEgrity and privacy considerations
We acknowledge that data integrity and privacy are of utmost importance to us and the people we intend to serve – both patients and medical professionals.
For that reason, we have strategically chosen to not make our MRI Analyzer an online, public-facing tool.
In order to best protect the privacy of and data of patients and their health information, we envision our product to be loaded onto an edge device disconnected from the Internet. This device will then read the MRI images and perform classification locally. Medical agencies can choose how to best protect patient identity and data on the edge device.
Our train, test, and validation dataset contain de-identified patient data and no patient identities were intentionally sought out for the purposes of building the MRI Analyzer.
NEWS
IN the NEWS: FDA Approval for AI and And Cancer Diagnosis
Cancer diagnosis AI just got a green light from the FDA
We believe the MRI Analyzer is riding the current technology-medicine innovation wave. As of October 2021, Paige, a digital diagnostics startup, got a preliminary go-ahead from the United States Food and Drug Administration (FDA) for its prostate cancer detection software. “Paige Prostate, an AI-based software for detecting prostate cancer, became the first product of its kind to receive FDA clearance…Paige’s FDA clearance is big news for other AI companies that specialize in digital diagnostics, but it raises thorny questions, too.”